



# NEWS RELEASE

**For Further Information:**

Virtus ETF Solutions

[etfinfo@virtus.com](mailto:etfinfo@virtus.com)

## **BioShares™ Biotechnology Products Fund and BioShares™ Biotechnology Clinical Trials Fund Announce Distribution**

**New York, NY, December 21, 2015** – The BioShares™ Biotechnology Products Fund (Ticker: BBP) and BioShares™ Biotechnology Clinical Trials Fund (Ticker: BBC), exchange-traded funds advised by Virtus ETF Advisers, LLC and subadvised by LifeSci Index Partners, LLC, today announced a distribution on its common stock as follows:

<u>Ticker</u>	<u>Per-Share Distribution</u>	<u>Declaration Date</u>	<u>Ex-Date</u>	<u>Record Date</u>	<u>Payable Date</u>
BBP	\$0.39725	12/18/2015	12/21/2015	12/23/2015	12/29/2015
BBC	\$0.14733	12/18/2015	12/21/2015	12/23/2015	12/29/2015

### **About the funds**

The [BioShares™ Biotechnology Products Fund](#) and [BioShares™ Biotechnology Clinical Trials Fund](#) seek investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index, respectively.

### **About LifeSci Index Partners**

[LifeSci Index Partners, LLC](#) is an index provider of healthcare-based stock market indices and also serves as the investment sub-advisor for the BioShares exchange traded funds. The principals of our firm are also founders of and/or are affiliated with LifeSci Advisors, a unique investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach.**About Virtus ETF Solutions**

[Virtus ETF Solutions](#), formerly ETF Issuer Solutions, an affiliate of Virtus Investment Partners, operates a multi-manager ETF platform, providing investors access to differentiated investment

capabilities from select subadvisers. Virtus ETF Advisers LLC serves as the investment advisor to the Funds. The Funds are distributed by ETF Distributors LLC, an affiliate of Virtus ETF Advisers LLC.

**Carefully consider the respective investment objectives, risk factors and charges and expenses of the BioShares™ Biotechnology Products Fund (the “Fund”) before investing. This and other information can be found in the Funds' prospectus, available at [www.bioshares.com](http://www.bioshares.com) or by calling 1-888-383-4184. Read the prospectus carefully before investing.**

Investing involves risk, including possible loss of principal.

The principal risks of investing in each Fund include biotechnology sector, market, index tracking, concentration, non-diversification and new adviser and sub-adviser risks, as well as fluctuations in net asset value. Funds that concentrate investments in a single sector will be more susceptible to factors affecting that sector and more volatile than funds that invest in many different sectors. The biotechnology sector in particular presents many investment risks including, but not limited to, heavy spending in research and development, government regulation, clinical trial risk, intellectual property risk, technological change and obsolescence, competition, product liability litigation and reimbursement risk. Funds that employ a passive investment strategy maintain investments in securities regardless of the current or projected performance of a specific security or sector which could cause the Funds' returns to be lower than if the Funds employed an active strategy.

BioShares™ Biotechnology Products Fund may be subject to greater sector risk than a more broad-based biotechnology fund because it focuses on a narrower category of the biotechnology sector consisting of issuers with a primary product offering or product candidate that has received U.S. Food and Drug Administration approval.

The NAV of the Fund is not necessarily the same as its intraday trading value. Fund investors should not expect to buy or sell shares at NAV because shares of ETFs such as the Fund are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Thus, shares may trade at a premium or discount to their NAV in the secondary market. Brokerage commissions will reduce returns.